The miR-34 family and its clinical significance in ovarian cancer
- PMID: 32047551
- PMCID: PMC6995379
- DOI: 10.7150/jca.33831
The miR-34 family and its clinical significance in ovarian cancer
Abstract
The tumor suppressor miR-34 family is transcriptionally induced by p53. Clinical significance of the various miR-34 family members has not been studied in ovarian cancer. In 228 ovarian cancers and in 19 non-neoplastic fallopian tube samples we analysed miR-34 a/b/c expression in relation to clinicopathological characteristics and clinical outcome. We found significantly lower levels of miR-34 a/b/c in ovarian cancers as compared to control-tissues (P=0.002, P<0.001, P<0.001, respectively). Expression of miR-34 b/c revealed an inverse correlation with BRCA1/2 mRNA-expression (BRCA1: miR34 b/c P=0.002 each; BRCA2: miR-34 b/c P<0.001 each), the same was true for miR-34a and BRCA2 mRNA-expression (P<0.001). The miR-34 family expression was found to be significantly lower in type 2 in comparison to type 1 cancers (P<0.001) and in TP53-mutated compared with TP53-wild-type ovarian cancers (P<0.001, P=0.002, P=0.004, respectively). When low grade serous ovarian cancers were compared with high grade serous cancers the respective miR-34 a/b/c expression was 2.6-, 40.8- and 32.3-fold higher. The expression of each of the miR-34 family members was revealed to be of independent prognostic relevance regarding progression free survival (PFS); miR-34a: HR 0.6, P=0.033; miR-34b: HR 0.2, P=0.001 and miR-34c: HR 0.3, P=0.002, respectively). For overall survival (OS) independency of the prognostic value was confined to miR-34b (HR 0.4, P=0.016) and miR-34c (HR 0.6, P=0.049). The independency of the prognostic value of our identified thresholds was confirmed for PFS for miR-34c in a publicly available dataset (NCBI Gene Expression Omnibus GSE73582). Our findings suggest that downregulation of miR-34 family is a crucial part in ovarian cancer development. Low miR-34 levels are linked to a worse overall survival and progression free survival and may indicate a more aggressive disease.
Keywords: carcinogenesis; miR-34; ovarian cancer; p53; survival.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures



Similar articles
-
[Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):885-90. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 22340095 Chinese.
-
Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.BMC Cancer. 2016 Feb 15;16:102. doi: 10.1186/s12885-016-2135-2. BMC Cancer. 2016. PMID: 26879132 Free PMC article.
-
Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer.PLoS One. 2015 Apr 20;10(4):e0124899. doi: 10.1371/journal.pone.0124899. eCollection 2015. PLoS One. 2015. PMID: 25894979 Free PMC article.
-
Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: A consideration on heterogeneity.Gene. 2019 Oct 20;716:144025. doi: 10.1016/j.gene.2019.144025. Epub 2019 Aug 5. Gene. 2019. PMID: 31394177 Review.
-
The Prognostic Value and Regulatory Mechanisms of microRNA-145 in Various Tumors: A Systematic Review and Meta-analysis of 50 Studies.Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):867-881. doi: 10.1158/1055-9965.EPI-18-0570. Epub 2019 Jan 2. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 30602498
Cited by
-
Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Functional Biomarkers Associated with Ovarian Cancer Risk.medRxiv [Preprint]. 2024 Feb 29:2024.02.26.24303311. doi: 10.1101/2024.02.26.24303311. medRxiv. 2024. Update in: Sci Rep. 2024 Dec 2;14(1):29937. doi: 10.1038/s41598-024-80173-z. PMID: 38464045 Free PMC article. Updated. Preprint.
-
Differential Impairment Mechanism of Sperm Production via Induction of miR-34c-Activated Apoptosis and Spermatogenesis Pathway in Diet-Induced Obesity and Resistant Mice and GC-1 Spg Cells.Int J Mol Sci. 2024 Jul 7;25(13):7451. doi: 10.3390/ijms25137451. Int J Mol Sci. 2024. PMID: 39000558 Free PMC article.
-
Genetic variants in oncogenic miRNA and 3' untranslated region of tumor suppressor genes: emerging insight into cancer genetics.Med Oncol. 2025 Jun 30;42(8):303. doi: 10.1007/s12032-025-02873-4. Med Oncol. 2025. PMID: 40587016 Review.
-
Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.Cell Cycle. 2022 Oct;21(20):2121-2131. doi: 10.1080/15384101.2022.2087755. Epub 2022 Jun 14. Cell Cycle. 2022. PMID: 35699451 Free PMC article. Review.
-
p53/MicroRNA-34 axis in cancer and beyond.Heliyon. 2023 Apr 3;9(4):e15155. doi: 10.1016/j.heliyon.2023.e15155. eCollection 2023 Apr. Heliyon. 2023. PMID: 37095919 Free PMC article. Review.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. - PubMed
-
- Marth C, Reimer D, Zeimet AG. Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Ann Oncol. 2017;28(suppl_8):viii36–viii9. - PubMed
-
- du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer. 2009;115(6):1234–44. - PubMed
-
- Pignata S, S CC, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii51–viii6. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous